

10 Apr 2019 | News

QUOTED. April 10, 2019. Lisa Stearns.

by

A new economic analysis found that targeted drug delivery (TDD) with Medtronic PLC's SynchroMed II drug infusion pump is associated with reduced health-care use and costs for patients with cancer pain compared to conventional medical management alone. See what study investigator Lisa Stearns of the Center for Pain and Supportive Care in Phoenix said about it here.

"The findings suggest that TDD is a cost-saving therapy that should be considered in patients with cancer for whom oral opioids are inadequate or produce intolerable adverse effects and should be expanded as health-care systems transition to value-based models." –Lisa Stearns, researcher, Center for Pain and Supportive Care

- Find out more: [Medtronic's SynchroMed II Infusion Pain Treatment Proves Cost-Effective In Study](#)

[Click here](#) for a free trial of *Medtech Insight*